SEARCH:   Advanced

Blood, 15 September 2004, Vol. 104, No. 6, pp. 1631-1638. Prepublished online as a Blood First Edition Paper on July 8, 2004May 25, 2004; DOI 10.1182/blood-2004-01-0360. This Article Full Text (PDF) All Versions of this Article: 2004-01-0360v1 2004-01-0360v2 104/6/1631    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dummer, R. Articles by Urosevic, M. Search for Related Content PubMed PubMed Citation Articles by Dummer, R. Articles by Urosevic, M. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted January 30, 2004 Accepted May 8, 2004 Adenovirus-mediated intralesional interferon- gene transfer induces tumor regressions in cutaneous lymphomas Reinhard Dummer*, Jessica C Hassel, Friederike Fellenberg, Stefan Eichmueller, Tanja Maier, Philippe Slos, Bruce Acres, Pascal Bleuzen, Vincent Bataille, Patrick Squiban, Guenter Burg, and Mirjana Urosevic Dermatology, University Hospital Zurich, Zurich, Switzerland Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany Transgene S.A., Strasbourg, France * Corresponding author; email: Reinhard.Dummer{at}usz.ch. Primary cutaneous lymphomas have been successfully treated with interferons (IFNs), counterbalancing the Th2-skewing state. We undertook a phase I, open-label, dose-escalating trial of repeated, intratumoral administration of TG1042 in patients with advanced primary cutaneous T cell lymphomas (CTCL) and multilesional cutaneous B cell lymphomas (CBCL). TG1042 is a third generation, non-replicating human adenovirus vector containing human IFN- cDNA insert. Nine patients (7 CTCL, 2 CBCL) were enrolled at the following TG1042 doses: 3x109, 3x1010, and 3x1011 total particles. Local clinical response was observed in 5/9 treated patients [3 patients with complete (CR) and 2 patients with partial response (PR)]. Out of these, 3 patients showed systemic CR, with the clearance of other non-injected skin lesions. Clinical response lasted for a median of 3 months (range 1-6 mo). Adverse events were mostly of grade 1 and 2. 7/9 treated patients had detectable TG1042-derived IFN- message in injected lesions after the first treatment cycle. TG1042-IFN- message was also detectable after several treatment cycles. We demonstrate the induction of humoral immune response to lymphoma tumor-antigen se70-2 posttreatment. Our study shows that intralesional injections of TG1042 are both safe and well tolerated. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Maby-El Hajjami, P. Ame-Thomas, C. Pangault, O. Tribut, J. DeVos, R. Jean, N. Bescher, C. Monvoisin, J. Dulong, T. Lamy, et al. Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase Cancer Res., April 1, 2009; 69(7): 3228 - 3237. [Abstract] [Full Text] [PDF] N. J. Senff, E. M. Noordijk, Y. H. Kim, M. Bagot, E. Berti, L. Cerroni, R. Dummer, M. Duvic, R. T. Hoppe, N. Pimpinelli, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas Blood, September 1, 2008; 112(5): 1600 - 1609. [Abstract] [Full Text] [PDF] D. J. Casso, S. Liu, D. D. Iwaki, S. K. Ogden, and T. B. Kornberg A Screen for Modifiers of Hedgehog Signaling in Drosophila melanogaster Identifies swm and mts Genetics, March 1, 2008; 178(3): 1399 - 1413. [Abstract] [Full Text] [PDF] J. Wu, X. Xiao, P. Zhao, G. Xue, Y. Zhu, X. Zhu, L. Zheng, Y. Zeng, and W. Huang Minicircle-IFN{gamma} Induces Antiproliferative and Antitumoral Effects in Human Nasopharyngeal Carcinoma Clin. Cancer Res., August 1, 2006; 12(15): 4702 - 4713. [Abstract] [Full Text] [PDF] K.-i. Yamanaka, R. Clark, R. Dowgiert, D. Hurwitz, M. Shibata, B. E. Rich, K. Hirahara, D. A. Jones, S. Eapen, H. Mizutani, et al. Expression of Interleukin-18 and Caspase-1 in Cutaneous T-Cell Lymphoma Clin. Cancer Res., January 15, 2006; 12(2): 376 - 382. [Abstract] [Full Text] [PDF] B. Acres, M. Gantzer, C. Remy, N. Futin, N. Accart, O. Chaloin, J. Hoebeke, J.-M. Balloul, and S. Paul Fusokine Interleukin-2/Interleukin-18, a Novel Potent Innate and Adaptive Immune Stimulator with Decreased Toxicity Cancer Res., October 15, 2005; 65(20): 9536 - 9546. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020